MedTrace Logo

Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms

NCT06305728 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2025-10-09

No results posted yet for this study

Summary

The purpose of this study is for researchers to find ways of detecting pancreatic ductal adenocarcinoma/PDAC early to avoid the invasive procedure of surgery. The study researchers think a combination of imaging and a series of blood tests may be an effective way to detect PDAC early. In this study, researchers will look at whether a combination of the following types of imaging with blood tests can detect PDAC in pancreatic cysts:

* The ImmunoPET scan (immune-positron emission tomography scan) with the imaging agent 89Zr-DFO-HuMab-5B1
* The HP MRI scan (hyperpolarized pyruvate magnetic resonance imaging scan)

Conditions

  • Pancreatic Cyst

Interventions

DIAGNOSTIC_TEST

89Zr-DFO-HuMab-5B1 immunoPET

Participants who choose to will undergo immunoPET before surgery.

DIAGNOSTIC_TEST

HP MRI

Participants who choose to will undergo HP MRI before surgery.

COMBINATION_PRODUCT

Blood assay

Will be drawn within 6 weeks of surgery and annually as post operative care

Sponsors & Collaborators

Principal Investigators

  • Kevin Soares, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-04
Primary Completion
2030-03-04
Completion
2030-03-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06305728 on ClinicalTrials.gov